Company profile: Arius Research
1.1 - Company Overview
Company description
- Provider of biotechnology solutions centered on the discovery and development of antibody therapeutics, primarily targeting breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma, leveraging its FunctionFIRST platform to identify monoclonal antibodies.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arius Research
Gennao Bio
HQ: United States
Website
- Description: Provider of genetic medicines developing targeted nucleic acid therapeutics for muscle diseases, featuring GMAB, a non-viral, cell-penetrating antibody technology that delivers nucleic acid payloads into cells targeting cancer and skeletal muscle disorders, and GMAB ADC for solid tumors, an antibody-drug conjugate demonstrated in preclinical studies to deliver cytotoxic drugs directly to tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gennao Bio company profile →
Ambit Biosciences
HQ: United States
Website
- Description: Provider of small molecule kinase inhibitor discovery and development for cancer, autoimmune, and inflammatory diseases, including quizartinib (AC220), a potent, selective FLT3 inhibitor for AML, AC410 (JAK2 inhibitor), and AC708 (CSF1R inhibitor), supported by the KinomeScan platform for screening kinase inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ambit Biosciences company profile →
Scorpion Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision oncology therapeutics, developing small-molecule inhibitors targeting the H1047X-mutant PI3Kα in solid tumors (STX-H1047-PI3Kα) and exon 20 insertion mutations in EGFR driving non-small cell lung cancer (STX-EGFR-EXON20).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scorpion Therapeutics company profile →
Immago
HQ: United Kingdom
Website
- Description: Provider of antibody-modulating enzyme approaches to enhance antibody-based cancer therapies, applying 'receptor refocusing' to modulate the endogenous antibody repertoire and enhance immune-mediated killing of cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immago company profile →
Admune Therapeutics
HQ: United States
Website
- Description: Provider of development and delivery of cytokine therapy drugs for cancer as a clinical-stage biotech company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Admune Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arius Research
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arius Research
2.2 - Growth funds investing in similar companies to Arius Research
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arius Research
4.2 - Public trading comparable groups for Arius Research
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →